{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:40:48Z","timestamp":1773816048065,"version":"3.50.1"},"reference-count":186,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"the CPRIT South Texas Center of Excellence in Cancer Research","doi-asserted-by":"publisher","award":["RP230419"],"award-info":[{"award-number":["RP230419"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Robert A. Welch Foundation","doi-asserted-by":"publisher","award":["BX-0048"],"award-info":[{"award-number":["BX-0048"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Currently, there are very few efficient treatment options for hepatobiliary pancreatic cancer (HPC), which comprises pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and hepatocellular carcinoma (HCC). The HPC tumors are the most lethal malignant tumors in the world. Traditional chemotherapy offers little survival benefit and is associated with notable systemic toxicity, which has made antibody\u2013drug conjugates (ADCs) a hopeful treatment option. Strong cytotoxic drugs combine with monoclonal antibodies to attack tumor-associated antigens. This review discusses the benefits and current developments of Antibody\u2013Drug Conjugates (ADCs) in treating HPC. It also covers their mechanisms of action, ongoing clinical trials, and the challenges of targeting specific antigens like B7-H3, c-MET, and Trop-2. ADCs deliver chemotherapy directly to cancer cells while protecting healthy tissues. It also addresses the favorable outcomes of several preclinical and clinical studies and highlights future paths to enhance ADC efficacy, including addressing tumor heterogeneity, overcoming resistance, and optimizing drug-delivery techniques. This approach has the possibility to further increase patient survival and minimize side effects in HPC patients. To the best of our knowledge and based on the available literature, we have made every effort to include all relevant publications; any inadvertent omissions are entirely unintentional.<\/jats:p>","DOI":"10.3390\/ijms27062707","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:35:57Z","timestamp":1773740157000},"page":"2707","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-3757","authenticated-orcid":false,"given":"Tushar","family":"Deb Nath","sequence":"first","affiliation":[{"name":"School of Integrative Biological and Chemical Sciences (SIBCS), University of Texas Rio Grande Valley, Edinburg, TX 78539, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attrayo","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Patia, Bhubaneswar 751024, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhash C.","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Division of Cancer Immunology and Microbiology, Medicine, and Oncology Integrated Service Unit, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA"},{"name":"South Texas Center of Excellence in Cancer Research (ST-CECR), McAllen, TX 78504, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2726-5127","authenticated-orcid":false,"given":"Debasish","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"School of Integrative Biological and Chemical Sciences (SIBCS), University of Texas Rio Grande Valley, Edinburg, TX 78539, USA"},{"name":"School of Earth, Environmental, and Marine Sciences (SEEMS), University of Texas Rio Grande Valley, Edinburg, TX 78539, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8962321","DOI":"10.1155\/2016\/8962321","article-title":"Pancreatic cancer epidemiology, detection, and management","volume":"2016","author":"Zhang","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_2","unstructured":"World Health Organization (WHO) (2025, December 29). Cancer. Available online: http:\/\/www.who.int\/cancer\/en\/."},{"key":"ref_3","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Riccardi, F., Dal Bo, M., Macor, P., and Toffoli, G. (2023). A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1274088"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Theocharopoulos, C., Lialios, P.P., Samarkos, M., Gogas, H., and Ziogas, D.C. (2021). Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. Vaccines, 9.","DOI":"10.3390\/vaccines9101111"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nature Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.6004\/jnccn.2009.0027","article-title":"NCCN clinical practice guidelines in oncology: Hepatobiliary cancers","volume":"7","author":"Benson","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_12","unstructured":"Moffitt Cancer Center (2025, December 29). Can Pancreatic Cancer Be Cured with Chemo?. Available online: https:\/\/www.moffitt.org\/cancers\/pancreatic-cancer\/faqs\/can-pancreatic-cancer-be-cured-with-chemo\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17588359241309461","DOI":"10.1177\/17588359241309461","article-title":"Innovative payloads for ADCs in cancer treatment: Moving beyond the selective delivery of chemotherapy","volume":"17","author":"Izzo","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_14","unstructured":"(2025, December 28). ADCs: The New Frontier in Cancer Treatment\u2014Pharmacy Times. Available online: https:\/\/www.pharmacytimes.com\/view\/adcs-the-new-frontier-in-cancer-treatment."},{"key":"ref_15","unstructured":"AstraZeneca (2025, December 29). Redefining Cancer Treatment with ADCs and Radioconjugates. Available online: https:\/\/www.astrazeneca.com\/what-science-can-do\/topics\/next-generation-therapeutics\/engineering-novel-cancer-treatments.html."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Aggarwal, D., Yang, J., Salam, M.A., Sengupta, S., Al-Amin, M.Y., Mustafa, S., Khan, M.A., Huang, X., and Pawar, J.S. (2023). Antibody-drug conjugates: The paradigm shifts in the targeted cancer therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1203073"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jjco\/hyae054","article-title":"Antibody-drug conjugates in solid tumors; new strategy for cancer therapy","volume":"54","author":"Takakura","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"mAbs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/mco2.671","article-title":"Antibody-drug conjugates in cancer therapy: Mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC Linker Chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-24-0426","article-title":"Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models","volume":"30","author":"Jain","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_25","unstructured":"(2025, December 29). The Bystander Effect of ADCs\u2014Biopharma PEG. Available online: https:\/\/www.biochempeg.com\/article\/269.html."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2306309","DOI":"10.1002\/advs.202306309","article-title":"Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors","volume":"11","author":"Guo","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix","volume":"140","author":"Stringhini","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_28","unstructured":"(2025, December 29). Non-Internalising Antibody\u2013Drug Conjugates-RSC Publishing. Available online: https:\/\/pubs.rsc.org\/en\/content\/articlehtml\/2022\/cs\/d2cs00446a."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lee, W. (2025). Recent Trends of ADCs. ADC Rev. J. Antib.-Drug Conjug.","DOI":"10.14229\/jadc.2025.01.30.030"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sinica B"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11684-024-1072-8","article-title":"Unlocking the potential of bispecific ADCs for targeted cancer therapy","volume":"18","author":"Zeng","year":"2024","journal-title":"Front. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Metrangolo, V., and Engelholm, L.H. (2024). Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. Cancers, 16.","DOI":"10.3390\/cancers16020447"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/2472555220912955","article-title":"Advances in Antibody\u2013Drug Conjugate Design: Current Clinical Landscape and Future Innovations","volume":"25","author":"Sassoon","year":"2020","journal-title":"SLAS Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mukherjee, A., and Bandyopadhyay, D. (2024). Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody-Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers, 16, Erratum in Cancers 2025, 17, 1633. https:\/\/doi.org\/10.3390\/cancers17101633.","DOI":"10.3390\/cancers17101633"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.3748\/wjg.v27.i20.2507","article-title":"RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets","volume":"27","author":"Chen","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ayasun, R., Ozer, M., and Sahin, I. (2023). The Role of HER2 Status in the Biliary Tract Cancers. Cancers, 15.","DOI":"10.3390\/cancers15092628"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.addr.2011.12.010","article-title":"Cancer stromal targeting (CAST) therapy","volume":"64","author":"Matsumura","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Koumprentziotis, I.-A., Theocharopoulos, C., Foteinou, D., Angeli, E., Anastasopoulou, A., Gogas, H., and Ziogas, D.C. (2024). New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3. Vaccines, 12.","DOI":"10.3390\/vaccines12010054"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s11605-017-3386-1","article-title":"Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3","volume":"21","author":"Hao","year":"2017","journal-title":"J. Gastrointest. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"12187","DOI":"10.18632\/aging.103395","article-title":"Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes","volume":"12","author":"Cao","year":"2020","journal-title":"Aging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12935-015-0195-z","article-title":"B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2\/STAT3\/Slug signaling pathway","volume":"15","author":"Kang","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Geerdes, E.E., Sideras, K., Aziz, M.H., van Eijck, C.H., Bruno, M.J., Sprengers, D., Boor, P.P.C., and Kwekkeboom, J. (2021). Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.615691"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Inamura, K., Takazawa, Y., Inoue, Y., Yokouchi, Y., Kobayashi, M., Saiura, A., Shibutani, T., and Ishikawa, Y. (2018). Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer. J. Clin. Med., 7.","DOI":"10.3390\/jcm7070172"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7-H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"27528","DOI":"10.1038\/srep27528","article-title":"Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4\/NF-kappaB pathway","volume":"6","author":"Xie","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"74856","DOI":"10.18632\/oncotarget.20421","article-title":"B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lutz, M.S., Zekri, L., Wessling, L., Berchtold, S., Heitmann, J.S., Lauer, U.M., Jung, G., and Salih, H.R. (2023). IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1163136"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jin, Y., Zhang, Z., Zou, S., Li, F., Chen, H., Peng, C., Deng, X., Wen, C., Shen, B., and Zhan, Q. (2021). A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.634881"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kogawa, T. (2025). The IDeate-PanTumor02 Investigators. IDeate-PanTumor02: A phase 1b\/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors [Abstract TPS3157]. J. Clin. Oncol., 43.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3157"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab Deruxtecan in Patients with Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_56","unstructured":"US National Library of Medicine (2025, December 21). A Study to Evaluate the Efficacy and Safety of Ifina-Tamab Deruxtecan (I-DXd) in Subjects with Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) (ClinicalTrials.gov Identifier NCT06330064), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06330064."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: A phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"ref_58","unstructured":"Mabwell (2025, December 23). Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 Presented at 2025 ESMO Congress [Press Release]. Available online: https:\/\/www.mabwell.com\/en\/news_info\/id-195.html."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2025.43.16_suppl.3036","article-title":"Results from a phase 1\/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102806","DOI":"10.1016\/j.ctrv.2024.102806","article-title":"Antibody-drug conjugates for hepato-pancreato-biliary malignancies:\u201cMagic bullets\u201d to the rescue?","volume":"129","author":"Theocharopoulos","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41401-024-01458-7","article-title":"Humanized dual-targeting antibody\u2013drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity","volume":"46","author":"Wang","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113379","DOI":"10.1016\/j.ejca.2023.113379","article-title":"Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response","volume":"195","author":"Bosi","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1158\/1078-0432.CCR-20-3210","article-title":"A MET Targeting antibody\u2013drug conjugate overcomes gemcitabine resistance in pancreatic cancer","volume":"27","author":"Cazes","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"25798","DOI":"10.1021\/acsomega.0c03102","article-title":"cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody\u2013Drug Conjugate Targeting c-Met Overexpression Tumors","volume":"5","author":"Min","year":"2020","journal-title":"ACS Omega"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"TPS3162","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3162","article-title":"Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met\u2013targeting antibody-drug conjugate, in select advanced solid tumor indications","volume":"42","author":"Perets","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Nyalali, A.M., Leonard, A.U., Xu, Y., Li, H., Zhou, J., Zhang, X., Rugambwa, T.K., Shi, X., and Li, F. (2023). CD147: An integral and potential molecule to abrogate hallmarks of cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1238051"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.nano.2017.09.012","article-title":"Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes","volume":"14","author":"Wang","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"439","DOI":"10.18632\/oncotarget.28421","article-title":"HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma","volume":"14","author":"Desai","year":"2023","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5019367","DOI":"10.1155\/2017\/5019367","article-title":"CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis","volume":"2017","author":"Peng","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000333825","article-title":"HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer","volume":"81","author":"Hirakawa","year":"2011","journal-title":"Oncology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djs501","article-title":"HER3 overexpression and survival in solid tumors: A meta-analysis","volume":"105","author":"Ocana","year":"2013","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/ijc.32273","article-title":"An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer","volume":"145","author":"Bourillon","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"67140","DOI":"10.18632\/oncotarget.18007","article-title":"Prognostic significance of HER3 in patients with malignant solid tumors","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_74","unstructured":"(2025, December 29). AMT-562, a Novel HER3-targeting Antibody\u2013Drug Conjugate. Available online: https:\/\/aacrjournals.org\/mct\/article\/22\/9\/1013\/728675\/AMT-562-a-Novel-HER3-targeting-Antibody-Drug."},{"key":"ref_75","first-page":"14","article-title":"HER3-targeted therapy: The mechanism of drug resistance and the development of anticancer drugs","volume":"7","author":"Zeng","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e70474","DOI":"10.1002\/cam4.70474","article-title":"Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated with Systemic Chemotherapy","volume":"13","author":"Satake","year":"2024","journal-title":"Cancer Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/15384047.2021.1916381","article-title":"The role of CD133 in hepatocellular carcinoma","volume":"22","author":"Liu","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bbrc.2020.03.009","article-title":"Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133(+) cells to vincristine and 5-fluorouracil through upregulation of BBC3","volume":"525","author":"Hemati","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","article-title":"CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway","volume":"27","author":"Ma","year":"2008","journal-title":"Oncogene"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.06.006","article-title":"The bad seed: Cancer stem cells in tumor development and resistance","volume":"28","author":"Koren","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Chen, H.Y., Luo, Z.L., Dong, L.W., Tan, Y.X., Yang, J.M., Feng, G.H., Wu, M.C., Li, Z., and Wang, H.Y. (2013). CD133\/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056878"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2013.07.021","article-title":"Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment","volume":"339","author":"Song","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00432-017-2436-0","article-title":"Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo","volume":"143","author":"Ma","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"51238","DOI":"10.18632\/oncotarget.17228","article-title":"Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s43066-024-00343-6","article-title":"Plasma CD24 level as a promising prognostic biomarker of hepatocellular carcinoma","volume":"14","author":"Rasmy","year":"2024","journal-title":"Egypt. Liver J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"167117","DOI":"10.1016\/j.bbadis.2024.167117","article-title":"Unraveling the role of CD24 in Hepatocellular carcinoma: Involvement of inactivated Hippo signaling and SOX4-mediated regulation","volume":"1870","author":"He","year":"2024","journal-title":"Mol. Basis Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s12672-024-01284-7","article-title":"CD24 affects the immunosuppressive effect of tumor-infiltrating cells and tumor resistance in a variety of cancers","volume":"15","author":"Zhao","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Nguyen, T.D., Bordeau, B.M., and Balthasar, J.P. (2023). Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 15.","DOI":"10.3390\/cancers15030713"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Huang, S., Zhang, X., Wei, Y., and Xiao, Y. (2024). Checkpoint CD24 function on tumor and immunotherapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1367959"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101086","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody\u2013drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1309\/HCQWPWD50XHD2DW6","article-title":"Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples","volume":"129","author":"Baumhoer","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_93","unstructured":"Hua, A. (2025, December 21). Antibody-Drug Conjugates (ADCs): Concepts and Challenges-Crown Bioscience. Available online: https:\/\/blog.crownbio.com\/antibody-drug-conjugates-concepts-and-challenges."},{"key":"ref_94","unstructured":"(2025, December 25). Overcoming Development Challenges in Antibody-Drug Conjugates. Available online: https:\/\/www.biocompare.com\/Editorial-Articles\/617005-Overcoming-Development-Challenges-in-Antibody-Drug-Conjugates\/."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.livres.2020.11.003","article-title":"Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma","volume":"4","author":"Shih","year":"2020","journal-title":"Liver Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Shirakawa","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiol. J. Immunopathol. Mol. Cell. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/hyb.1992.11.539","article-title":"Biochemical Characterization of Trop-2, a Cell Surface Molecule Expressed by Human Carcinomas: Formal Proof That the Monoclonal Antibodies T16 and MOv-16 Recognize Trop-2","volume":"11","author":"Alberti","year":"1992","journal-title":"Hybridoma"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-05-1961","article-title":"Clinical Significance of TROP2 Expression in Colorectal Cancer","volume":"12","author":"Ohmachi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","volume":"99","author":"Fong","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jcp.2008.060590","article-title":"TROP2 expression as prognostic marker for gastric carcinoma","volume":"62","author":"Spizzo","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/modpathol.3801001","article-title":"TROP2: A novel prognostic marker in squamous cell carcinoma of the oral cavity","volume":"21","author":"Fong","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7","article-title":"Human Trop-2 is a tumor-associated calcium signal transducer","volume":"76","author":"Ripani","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ijc.2910620520","article-title":"Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas","volume":"62","author":"Fornaro","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","article-title":"Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients","volume":"46","author":"Bignotti","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"mAbs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1535-7163.MCT-11-0115","article-title":"Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models","volume":"10","author":"Sharkey","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1535-7163.MCT-16-0431","article-title":"RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models","volume":"15","author":"Strop","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers3021513","article-title":"Epidermal growth factor receptor in pancreatic cancer","volume":"3","author":"Newman","year":"2011","journal-title":"Cancers"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"33446","DOI":"10.18632\/oncotarget.26002","article-title":"RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models","volume":"9","author":"Wong","year":"2018","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11523-018-0616-8","article-title":"Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy","volume":"14","author":"Li","year":"2019","journal-title":"Target. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41416-020-01046-6","article-title":"Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer","volume":"123","author":"Greene","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CJI.0b013e3182562d76","article-title":"Monoclonal antibody therapy of pancreatic cancer with cetuximab: Potential for immune modulation","volume":"35","author":"Luedke","year":"2012","journal-title":"J. Immunother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1021\/acs.jmedchem.1c01920","article-title":"Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer","volume":"65","author":"Zhu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/cam4.1064","article-title":"Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma","volume":"6","author":"Lu","year":"2017","journal-title":"Cancer Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","article-title":"Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer","volume":"122","author":"Nishigaki","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.neo.2021.07.006","article-title":"A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma","volume":"23","author":"Munekage","year":"2021","journal-title":"Neoplasia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature14581","article-title":"Glypican-1 identifies cancer exosomes and detects early pancreatic cancer","volume":"523","author":"Melo","year":"2015","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.18632\/oncotarget.26620","article-title":"Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases","volume":"10","author":"Lucien","year":"2019","journal-title":"Oncotarget"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"C846","DOI":"10.1152\/ajpcell.00290.2021","article-title":"Role of glypican-1 in regulating multiple cellular signaling pathways","volume":"321","author":"Pan","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1158\/1535-7163.MCT-21-0335","article-title":"Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer","volume":"20","author":"Tsujii","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.asjsur.2012.08.001","article-title":"GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer","volume":"36","author":"Duan","year":"2013","journal-title":"Asian J. Surg."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Faust, J.R., Hamill, D., Kolb, E.A., Gopalakrishnapillai, A., and Barwe, S.P. (2022). Mesothelin: An Immunotherapeutic Target beyond Solid Tumors. Cancers, 14.","DOI":"10.3390\/cancers14061550"},{"key":"ref_134","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1535-7163.MCT-16-0449","article-title":"Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET","volume":"16","author":"Ogasawara","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"TPS540","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS540","article-title":"An open-label, phase II study of intravenous anetumab ravtansine, an anti-mesothelin antibody drug conjugate, in pretreated mesothelin-expressing advanced pancreatic cancer","volume":"36","author":"Chokshi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1200\/JCO.2022.40.16_suppl.4136","article-title":"Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208","volume":"40","author":"Spiliopoulou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10637-024-01430-6","article-title":"A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer","volume":"42","author":"Ko","year":"2024","journal-title":"Investig. New Drugs"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tibs.2018.09.008","article-title":"The Claudins: From Tight Junctions to Biological Systems","volume":"44","author":"Tsukita","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e32882","DOI":"10.1097\/MD.0000000000032882","article-title":"The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes","volume":"102","author":"Kayikcioglu","year":"2023","journal-title":"Medicine"},{"key":"ref_144","first-page":"1031","article-title":"Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients","volume":"37","author":"Zhang","year":"2022","journal-title":"Histol. Histopathol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jclinpath-2011-200400","article-title":"Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: Association with features of differentiation","volume":"65","author":"Soini","year":"2012","journal-title":"J. Clin. Pathol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms","volume":"134","author":"Schlitter","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/1538-7445.AM2021-1204","article-title":"SO-N102, a novel CLDN18. 2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels","volume":"81","author":"Sadilkova","year":"2021","journal-title":"Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/1538-7445.AM2023-6300","article-title":"Therapeutic potential of EO-3021\/SYSA1801, a Claudin18. 2 antibody-drug conjugates, for the treatment of CLDN18. 2-expressing cancers","volume":"83","author":"Dan","year":"2023","journal-title":"Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","article-title":"First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","article-title":"Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer","volume":"13","author":"Khorana","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/bjs.1800820831","article-title":"Tissue factor expression correlates with histological grade in human pancreatic cancer","volume":"82","author":"Kakkar","year":"1995","journal-title":"Br. J. Surg."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13046-023-02868-x","article-title":"Antibody drug conjugates: Hitting the mark in pancreatic cancer?","volume":"42","author":"Wittwer","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1111\/cas.14146","article-title":"Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models","volume":"110","author":"Tsumura","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3892\/or.2020.7850","article-title":"Antitumor effect of humanized anti-tissue factor antibody-drug conjugate in a model of peritoneal disseminated pancreatic cancer","volume":"45","author":"Tsumura","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"59086","DOI":"10.18632\/oncotarget.19175","article-title":"Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S0959-8049(22)01043-7","article-title":"A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): Initial results from the dose-escalation stage","volume":"174","author":"Ulahannan","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"583","DOI":"10.7150\/ijms.32751","article-title":"Expression of Chosen Carcinoembryonic-Related Cell Adhesion Molecules in Pancreatic Intraepithelial Neoplasia (PanIN) Associated with Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"16","author":"Romaniuk","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-09-0586","article-title":"CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates","volume":"15","author":"Govindan","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Knutson, S., Raja, E., Bomgarden, R., Nlend, M., Chen, A., Kalyanasundaram, R., and Desai, S. (2016). Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157762"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors","volume":"26","author":"DeDecary","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1038\/s41598-018-32601-0","article-title":"Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin","volume":"8","author":"Fuchigami","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Najjar, M.K., Manore, S.G., Regua, A.T., and Lo, H.W. (2022). Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. Genes, 13.","DOI":"10.3390\/genes13112065"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Han, S.H., Ryu, K.H., and Kwon, A.Y. (2021). The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma-HER2 Protein and Gene in Pancreatic Cancer. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040653"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"eadq0513","DOI":"10.1126\/sciadv.adq0513","article-title":"Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models","volume":"11","author":"Metrangolo","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1172\/JCI120481","article-title":"Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release","volume":"128","author":"Szot","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ijc.29492","article-title":"Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts","volume":"137","author":"Koga","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/2159-8290.CD-14-0474","article-title":"Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions","volume":"5","author":"Liou","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2002852","DOI":"10.1002\/advs.202002852","article-title":"A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer","volume":"7","author":"Huang","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-023-00447-z","article-title":"Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma","volume":"7","author":"Zhu","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.bjc.6605107","article-title":"Type IV Collagen Is a Tumour Stroma-Derived Biomarker for Pancreas Cancer","volume":"101","author":"Ohlund","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12967-016-0920-y","article-title":"Diffusion-weighted and dynamic contrast-enhanced MRI of pancreatic adenocarcinoma xenografts: Associations with tumor differentiation and collagen content","volume":"14","author":"Wegner","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1021\/bc200158j","article-title":"Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue","volume":"22","author":"Yasunaga","year":"2011","journal-title":"Bioconjugate Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_175","unstructured":"(2025, December 29). GLOBOCAN. Available online: http:\/\/globocan.iarc.fr\/Default.aspx."},{"key":"ref_176","unstructured":"ClinicalTrials.gov (2025, December 29). Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care in Advanced HER2-Expressing Biliary Tract Cancer (DESTINY-BTC01), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06467357."},{"key":"ref_177","unstructured":"Innovent Biologics (2025, December 21). IBI-3001 (B7-H3\u00d7EGFR Bispecific ADC) in Advanced Solid Tumors (Clinical Trial Registration No. NCT06349408), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06349408."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1158\/1538-7445.AM2024-2621","article-title":"Preclinical Efficacy of DM002, a bispecific HER3 \u00d7 MUC1 antibody-drug conjugate with a novel DNA topoisomerase I inhibitor, in solid tumor models [abstract]","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2025.43.16_suppl.3001","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR \u00d7 HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Masugi, Y. (2022). The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities. Cancers, 14.","DOI":"10.3390\/cancers14133293"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.3332\/ecancer.2025.1996","article-title":"Targeting stromal components in pancreatic ductal adenocarcinoma: A review","volume":"19","author":"Shihadeh","year":"2025","journal-title":"Ecancermedicalscience"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemis tries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Seo, H., Go, D., Jung, S.Y., Han, S., Nguyen, V.Q., Kwak, M., and Um, W. (2025). Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. Biomolecules, 15.","DOI":"10.3390\/biom15101477"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Zubair, T., and Bandyopadhyay, D. (2023). Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032651"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Shetu, S.A., and Bandyopadhyay, D. (2022). Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073706"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2707\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:43:19Z","timestamp":1773812599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":186,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27062707"],"URL":"https:\/\/doi.org\/10.3390\/ijms27062707","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}